Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Biogen achieve all milestone payments for the HI-Bio acquisition by end of 2026?
Yes • 50%
No • 50%
Biogen's financial disclosures or reliable financial news sources
Biogen to Acquire Human Immunology Biosciences for $1.15 Billion Upfront, Up to $1.8 Billion Total
May 22, 2024, 12:21 PM
Biogen Inc. has announced an agreement to acquire Human Immunology Biosciences (HI-Bio), a privately-held clinical-stage biotechnology company based in South San Francisco, for $1.15 billion upfront and up to $650 million in potential milestone payments. This acquisition aims to bolster Biogen's late-stage pipeline and expand its immunology portfolio. HI-Bio specializes in targeted therapies for immune-related diseases, including the development of the anti-CD38 antibody Felzartamab and the C5aR1 program. The deal underscores Biogen's strategic shift towards immunology and immune-mediated disorders, diversifying its focus beyond its traditional neuroscience roots. This move continues Biogen's shape-shifting under CEO Chris Viehbacher.
View original story
Less than $200 million • 25%
$200 million to $400 million • 25%
$400 million to $600 million • 25%
More than $600 million • 25%
Fully integrated by mid-2025 • 25%
Fully integrated by end of 2025 • 25%
Integration delayed beyond 2025 • 25%
Integration halted or reversed • 25%
Yes • 50%
No • 50%
Full $1.7 billion paid • 33%
Partial milestone payments made • 33%
No milestone payments made • 34%
No milestones achieved • 33%
Only first milestone achieved • 33%
All milestones achieved • 33%
Yes • 50%
No • 50%
Biosimilars launched • 50%
Biosimilars not launched • 50%
Approved • 50%
Not Approved • 50%
No • 50%
Yes • 50%
Decrease by less than 5% • 25%
Decrease by more than 5% • 25%
Increase by more than 5% • 25%
Increase by less than 5% • 25%
Increase by more than 10% • 25%
Decrease by more than 10% • 25%
Decrease by less than 10% • 25%
Increase by less than 10% • 25%